จำนวน 13 ความเห็น, หน้า่ | -1-

ความเห็นเพิ่มเติมที่ 1 21 มิ.ย. 2547 (20:54)
Brachytherapy เป็นการรักษาโดยใช้รังสีแบบหนึ่ง ที่เพิ่มปริมาณกัมมันตภาพรังสี เพื่อเพิ่มประสิทธิภาพในการรักษาโดยไม่ทำร้ายเนื้อเยื่อปกติ brachy แปลว่า สั้น หมายถึงว่าการรักษาโดยใช้รังสีนี้ จำกัดอยู่ในระยะสั้นๆ ทำให้ผลกระทบต่อเนื้อเยื่อปกติมีลดลง และทำให้เพิ่มปริมาณรังสีได้

half-life คือเวลาที่สารรังสี หรือยา จะย่อยสลายลงครึ่งหนึ่งของปริมาณเริ่มต้น

ความเห็นเพิ่มเติมที่ 2 5 ก.ค. 2547 (06:26)
ASX/MEDIA RELEASE 1 July 2004

New Australian Patent Granted BioSilicon™ Information Carrier Global nanotechnology company pSivida Limited (ASX: PSD), is pleased to announce that its UK operating subsidiary pSiMedica Limited has been granted a new Australian patent for BioSiliconTM. Australian Patent Number 769952 provides protection for an orally administrable pharmaceutical product comprising an information carrier having a form and composition such that information is recorded by the carrier, wherein the information carrier comprises a material that is resistant to the gastric environment thereby protecting this information.

One potential application of the carrier is in the treatment of overdose patients who have consumed large quantities of a pharmaceutical product. It is essential for doctors treating such a patient to be able to identify the drug as soon as possible so that remedial action can be taken. Information about the drug, the dosage of the drug, batch number, and its expiry date may be of value. Once retrieved from the patient the information present on the carrier may be read using a microscope. The information carrier would comprise a semiconductor chip or a silicon chip. The information would be recorded by engraving the chip via photolithography or electron beam lithography. Using a semi conductor we are able to engrave large quantities of information on very small samples of less than 10 microns.

pSivida Managing Director Gavin Rezos said, “This patent demonstrates another exciting potential application for BioSiliconTM within the field of healthcare. BioSiliconTM is an ideal biomaterial for such an application. Silicon has been shown to have high levels of resistance to gastric corrosion, we are able to impart large quantities of information on an extremely small surface utilizing proven techniques used in electronics and we are also able to control the rate of biodegration of the information carrier for a suitable period after the drug has been administered.” pSiMedica has also recently been granted a further patent in New Zealand for the use of BioSiliconTM as a vehicle for transferring material into a cell providing additional protection in drug delivery applications.

The pSiMedica Intellectual Property portfolio now consists of 21 patent families, 16 granted patents and over 85 patent applications. pSiMedica owns all of the Intellectual Property (royalty free) for the application of BioSiliconTM.

Products protected by patents and patent applications owned by pSiMedica include materials comprising bioactive, resorbable and biocompatible silicon that are of value in the fabrication of new generations of intelligent drug delivery devices, orthopaedic implants and intelligent diagnostic tools.

-ENDS-

Released by:
Josh Mann
Investor Relations
pSivida Limited
Tel: + 61 8 9226 5099
joshuamann@psivida.com.au


#####

ความเห็นเพิ่มเติมที่ 3 5 ก.ค. 2547 (06:29)
NOTES TO EDITORS:

pSivida Limited

pSivida is an Australian-based biotechnology company committed to the biomedical applications of nano-technology and which has as its core focus the development and commercialisation of nano-structured porous silicon (BioSilicon™) in biocompatible and biodegradable forms for use in healthcare through its wholly owned UK subsidiary pSiMedica Limited. BioSilicon™ has multiple potential applications across the high growth healthcare sector, including controlled drug delivery, brachytherapy, tissue engineering and orthopaedics.

pSivida is listed on the Australian Stock Exchange (ASX Code: PSD) and in Germany on the Frankfurt Stock Exchange on the XETRA system (German Symbol: PSI. Securities Code (WKN) 358705). pSivida’s shares also trade in the United Kingdom on the OFEX International Market Service (IMS) under the ticker symbol PSD.

For more information visit www.psivida.com.au


#####

pSiMedica Limited (UK)

pSiMedica has identified a biocompatible and biodegradable form of silicon (BioSilicon™). The technology is based on applying a modified form of the silicon chip (porosified or nano-structured silicon) in a variety of healthcare applications, ranging from controlled drug delivery, brachytherapy, tissue engineering and orthopaedics to clinical diagnostics.

pSiMedica’s market strength lies in its international management and science team, including former Chairman of SmithKline & French Research, Dr Roger Brimblecombe, former PepTech CEO Dr Roger Aston, and, the world eminent scientist and the inventor of BioSilicon™, Professor Leigh Canham. The Company has access to cutting edge research and development facilities of QinetiQ plc, the largest science and technology company in Europe.

pSiMedica owns the worldwide intellectual property rights to nano-structured porous silicon, known as BioSilicon™, for use in or on humans and is dedicated to realising the potential of porous silicon products in areas such as controlled drug delivery, diagnostics and orthopaedics.

For more information visit www.psimedica.co.uk


#####

ความเห็นเพิ่มเติมที่ 4 5 ก.ค. 2547 (06:30)
02 June 04

QinetiQ\'s first joint venture deal reaps value from nanotechnology

pSiMedica

QinetiQ, Europe\'s largest science and technology organisation, has agreed to exchange its stake in the biotechnology company pSiMedica Limited for shares in Australian-based pSivida Limited. pSiMedica was established as a joint venture between QinetiQ and pSivida in 2000 to exploit the potential of BioSiliconTM, a form of nanostructured porous silicon with a broad range of medical applications, including the localised treatment of cancer (brachytherapy).

The transaction values pSiMedica at £40 million. Under the terms of the agreement QinetiQ will receive Aus$4.32 million in cash and 35.7 million pSivida shares at Aus$1.09 per share, which equates to a 17.6% stake in the company. QinetiQ has also agreed to retain more than a half of its stake in pSivida for at least one year after the transaction closes. QinetiQ\'s investment director, Stephen Lake, will be appointed as a non-executive director of pSivida.

Subject to pSivida shareholder approval, pSivida will also acquire shares currently held by all other minority pSiMedica shareholders, resulting in 100% ownership of pSiMedica. Minority pSiMedica shareholders will receive pSivida shares only.

Welcoming the deal, Sir John Chisholm, QinetiQ\'s chief executive, said: "This agreement exemplifies our policy of unlocking the value of QinetiQ\'s technology base by fast-tracking \'hot\' technologies in a programme that includes joint ventures and spin outs. Our transaction with pSivida - the first to arise from this programme - allows us to realise immediate value from our pSiMedica investment while we continue to hold a major stake in the future success of pSivida\'s BioSiliconTM platform."

Stephen Lake added: "Thanks to the investment from both QinetiQ and pSivida, pSiMedica is in a strong position to make a very real difference in healthcare through the development of BioSiliconTM. I look forward to continuing to support this important work through my place on the pSivida board."

pSivida Managing Director, Gavin Rezos, commented: "We are extremely pleased to have been able to acquire the balance of pSiMedica and move to a more simplified ownership structure. It is an outcome that both shareholders and investors had been looking for and will also broaden pSivida\'s appeal with institutional investors, particularly as pSivida looks to list both in the US and the UK. We welcome QinetiQ\'s continuing interest in both pSivida and pSiMedica and look forward to maintaining the strong relationship we share."

The first clinical trials of pSiMedica\'s BioSiliconTM product, BrachySilTM, began last month (May 2004) at the Singapore General Hospital. This is the first evaluation of BioSiliconTM in man and involves patients with inoperable primary liver cancer. The trial is being run through pSiOncology Pte Limited, a wholly owned subsidiary of pSiMedica.


Notes for Editors:

pSivida Limited is an Australian-based biotechnology company committed to the biomedical applications of nano-technology and which has as its core focus the development and commercialisation of nano-structured porous silicon (BioSiliconTM) in biocompatible and biodegradable forms for use in human and animal healthcare, formerly through its UK subsidiary pSiMedica Limited in conjunction with QinetiQ. As a true \'platform technology\', BioSiliconTM has multiple potential applications across the high growth healthcare sector, including controlled drug delivery, brachytherapy, tissue engineering and orthopaedics. pSivida is listed on the Australian Stock Exchange (ASX Code: PSD). pSivida is also listed in Germany on the Frankfurt Stock Exchange on XETRA system, as well as Berlin, Munich and Stuttgart, (German Symbol: PSI. Securities Code (WKN) 358705). For more information visit www.psivida.com.au

> pSivida

Press Officer: Nicole Louth-Davies


#####

ความเห็นเพิ่มเติมที่ 5 5 ก.ค. 2547 (06:34)
J Am Chem Soc. 2004 Jun 30;126(25):7935-9.

Doughnut-shaped peptide nano-assemblies and their applications as nanoreactors.

Djalali R, Samson J, Matsui H.

Department of Chemistry and Biochemistry at Hunter College and the Graduate Center, The City University of New York, New York, New York 10021, USA.

Doughnut-shaped nanoreactors, peptide nano-doughnuts, were self-assembled from peptides and organic Au salts. We demonstrated that monodisperse Au nanocrystals were synthesized inside the cavities of peptide nano-doughnuts by the reduction of Au ions and the size of the Au nanocrystal was controlled by the cavity dimension. The Au nanocrystals inside the nano-doughnuts were extracted by destroying the nano-doughnuts via long UV irradiation (>10 h). These features may allow the peptide nano-doughnuts to be applied in the fields of nanomaterial syntheses, controlled release systems, and drug delivery.


#####

ความเห็นเพิ่มเติมที่ 6 5 ก.ค. 2547 (06:41)
Hua Xi Kou Qiang Yi Xue Za Zhi. 2004 Apr;22(2):93-5.

[Genotoxicity of a new NanoHA-PA66 root filling material in vitro]

[Article in Chinese]

Ye L, Su Q, Zhou XD, Tan H.

Dept. of Endodontics, West China College of Stomatology, Sichuan University, Chengdu 610041, China.

OBJECTIVE: The micronucleus test was applied to evaluate the genotoxicity of a new nanocomplex HA-PA66 root filling material in vitro. METHODS: The dulbecco\'s modified eagle media(DMEM) extracts of the powder part and the mixture of the new nanomaterial were prepared separately. The V79 cell was used as the test cell and the mitomycin C(MMC) as the positive control. The MTT assay was employed in our study to evaluate the cytotoxic effect while the number of micronucleus was used as the criteria for the detection of genotoxocity. RESULTS: The MTT values in test groups and negative group were not significantly different at different times (P > 0.05). The number of micronucleus in test groups (powder group: 6.1 +/- 1.1/1,000; complex group: 5.7 +/- 0.6/1,000) was similar to the negative control(5.3 +/- 0.8/1,000, P > 0.05), while they were significantly different to the positive control(123.9 +/- 8/1,000, P < 0.05). CONCLUSION: The new nanocomplex HA-PA66 root filling material showed no detectable cytotoxic and genotoxic effects in this study and was proved to be biocompatible.


#####

ความเห็นเพิ่มเติมที่ 7 5 ก.ค. 2547 (06:45)
Annu Rev Phys Chem. 2004;55:159-96.

FUNCTIONAL OXIDE NANOBELTS: Materials, Properties and Potential Applications in Nanosystems and Biotechnology.

Wang ZL.

School of Materials Science and Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332-0245; email: zhong.wang@mse.gatech.edu

Nanobelt is a quasi-one-dimensional structurally controlled nanomaterial that has well-defined chemical composition, crystallographic structure, and surfaces (e.g., growth direction, top/bottom surface, and side surfaces). This article reviews the nanobelt family of functional oxides, including ZnO, SnO2, In2O3, Ga2O3, CdO, and PbO2 and the relevant hierarchical and complex nanorods and nanowires that have been synthesized by a solid-vapor process. The nanobelts are single crystalline and dislocation free, and their surfaces are atomically flat. The oxides are semiconductors that have been used for fabrication of nanosize functional devices of key importance for nanosystems and biotechnology, such as field-effect transistors, gas sensors, nanoresonators, and nanocantilevers. The structurally controlled ZnO nanobelts that exhibit piezoelectric properties are also reviewed. By controlling growth kinetics, we show the success of growing nanobelt-based novel structures whose surfaces are dominated by the polarized +-(0001) facets. Owing to the positive and negative ionic charges on the zinc- and oxygen-terminated +-(0001) surfaces, respectively, a spontaneous polarization is induced across the nanobelt thickness. As a result, helical nanostructures and nanorings are formed by rolling up single-crystal nanobelts; this phenomenon is a consequence of minimizing the total energy contributed by spontaneous polarization and elasticity. The polar surface-dominated ZnO nanobelts are likely to be an ideal system for understanding piezoelectricity and polarization-induced ferroelectricity at nano-scale and they could have applications as one-dimensional nano-scale sensors, transducers, and resonators.


#####

ความเห็นเพิ่มเติมที่ 8 5 ก.ค. 2547 (06:48)
Proc Natl Acad Sci U S A. 2003 May 13;100(10):5597-600. Epub 2003 May 05.

Materials become insensitive to flaws at nanoscale: lessons from nature.

Gao H, Ji B, Jager IL, Arzt E, Fratzl P.

Max Planck Institute for Metals Research, Heisenbergstrasse 3, D-70569 Stuttgart, Germany. hjgao@mf.mpg.de

Natural materials such as bone, tooth, and nacre are nanocomposites of proteins and minerals with superior strength. Why is the nanometer scale so important to such materials? Can we learn from this to produce superior nanomaterials in the laboratory? These questions motivate the present study where we show that the nanocomposites in nature exhibit a generic mechanical structure in which the nanometer size of mineral particles is selected to ensure optimum strength and maximum tolerance of flaws (robustness). We further show that the widely used engineering concept of stress concentration at flaws is no longer valid for nanomaterial design.


#####

ความเห็นเพิ่มเติมที่ 9 12 ก.ค. 2547 (10:08)
The BBC is reporting on nanotech being used for a novel therapy delivery system. The company pSivida is developing BrachySil, a bio-silicon, nanoscale, brachytherapy solution. Brachytherapy is a special type of radiation treatment for cancer patients. BrachySil is manufactured by embedding the pores of silicon with phosphorus. This is then irradiated in a reactor, creating phosphorus-32 for the treatment. Phosphorus-32 has a 2 week half life, almost six times as long as conventional therapy. The bio-silicon is then directed to the tumour by a needle injection.

Lab tests have shown promise, namely that BrachySil is very well retained within liver tissue with little or no radioactivity reaching surrounding tissue or the blood stream, and that therapy killed tissue within a very well-defined radius of application. Human trials have begun in Singapore. Currently there are two liver cancer patients being treated, with plans for ten more. Results are expected by October 2004, with the product reaching market in 2006. Long term plans are to target also brain and pancreas tumors.

There are some interesting photos at the pSivida site of the first patient receiving treatment.


#####

ความเห็นเพิ่มเติมที่ 10 14 ก.ย. 2547 (12:33)
อ่านแล้วไม่เห็นจะเข้าใจเลย

ความเห็นเพิ่มเติมที่ 11 26 ก.ย. 2547 (11:21)
น่าจะมีเร็วกว่านี้คนตายเยอะแล้ว

ความเห็นเพิ่มเติมที่ 12 12 ก.ค. 2548 (15:53)
อยากได้ข้อมูลที่เป็นหนังสือช่วยแนะนำหน่อยได้ไหมคะ
ว่าจะอ่านได้จากหนังสืออะไร..ขอบคุณค่ะ

ความเห็นเพิ่มเติมที่ 13 27 ม.ค. 2549 (11:08)
ช่วยแปลเป็นไทยได้ไหมค่ะ อ่านไม่รุ้เรื่อง